{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:03:29Z","timestamp":1764306209122,"version":"3.32.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13273-8","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:01:11Z","timestamp":1736330471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-8894","authenticated-orcid":false,"given":"R\u016bta","family":"Everatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Kuzmickien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birut\u0117","family":"Brasi\u016bnien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieva","family":"Vincer\u017eevskien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birut\u0117","family":"Intait\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulius","family":"Cic\u0117nas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrida","family":"Lisauskien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"13273_CR1","doi-asserted-by":"crossref","unstructured":"Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM et al. American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on the Kidney in Cardiovascular Disease. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46\u2013e57.","DOI":"10.1161\/HYP.0000000000000224"},{"issue":"2","key":"13273_CR2","first-page":"89","volume":"52","author":"R Radi\u0161auskas","year":"2016","unstructured":"Radi\u0161auskas R, Kuzmickien\u0117 I, Milinavi\u010dien\u0117 E, Everatt R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Med (Kaunas). 2016;52(2):89\u201398.","journal-title":"Med (Kaunas)"},{"issue":"8","key":"13273_CR3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","volume":"287","author":"RS Vasan","year":"2002","unstructured":"Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D\u2019Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287(8):1003\u201310.","journal-title":"JAMA"},{"key":"13273_CR4","unstructured":"Digital publication. Health of Population of Lithuania, ISSN 2669\u2009\u2013\u20091566. Statistics Lithuania, 2020. https:\/\/osp.stat.gov.lt\/en\/lietuvos-gyventoju-sveikata-2020\/kai-kuriu-letiniu-ligu-ir-bukliu-paplitimas. Last accessed on 14 November 2023."},{"issue":"33","key":"13273_CR5","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, ESC Scientific Document Group, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"key":"13273_CR6","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group, the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. ;. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and 2022;23(10):e333-e465. https:\/\/doi.org\/10.1093\/ehjci\/jeac106. Erratum in: Eur Heart J Cardiovasc Imaging. 2023;24(6):e98. https:\/\/doi.org\/10.1093\/ehjci\/jead080.","DOI":"10.1093\/ehjci\/jeac106 10.1093\/ehjci\/jead080"},{"key":"13273_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.phrs.2019.01.037","volume":"141","author":"M Tadic","year":"2019","unstructured":"Tadic M, Cuspidi C, Belyavskiy E, Grassi G. Intriguing relationship between antihypertensive therapy and cancer. Pharmacol Res. 2019;141:501\u201311.","journal-title":"Pharmacol Res"},{"issue":"6","key":"13273_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","volume":"37","author":"S Holmes","year":"2013","unstructured":"Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population\u2013based retrospective cohort study. Cancer Epidemiol. 2013;37(6):881\u20135.","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"13273_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41419-020-2675-x","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, et al. Enalapril overcomes chemoresistance and potentiates antitumour efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-\u03baB\/STAT3-regulated proteins. Cell Death Dis. 2020;11(6):477.","journal-title":"Cell Death Dis"},{"key":"13273_CR10","doi-asserted-by":"publisher","first-page":"113287","DOI":"10.1016\/j.biopha.2022.113287","volume":"153","author":"D Felkle","year":"2022","unstructured":"Felkle D, Jarczy\u0144ski M, Kaleta K, Zi\u0119ba K, Nazimek K. The immunomodulatory effects of antihypertensive therapy: a review. Biomed Pharmacother. 2022;153:113287.","journal-title":"Biomed Pharmacother"},{"issue":"15","key":"13273_CR11","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1002\/cam4.4088","volume":"10","author":"R Balkrishnan","year":"2021","unstructured":"Balkrishnan R, Desai RP, Narayan A, Camacho FT, Flausino LE, Chammas R. Associations between initiating antihypertensive regimens on stage I\u2013III colorectal cancer outcomes: a Medicare SEER cohort analysis. Cancer Med. 2021;10(15):5347\u201357.","journal-title":"Cancer Med"},{"issue":"2","key":"13273_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10552-021-01527-w","volume":"33","author":"T Eskelinen","year":"2022","unstructured":"Eskelinen T, Veitonm\u00e4ki T, Kotsar A, Tammela TLJ, P\u00f6yh\u00f6nen A, Murtola TJ. Improved renal cancer prognosis among users of drugs targeting renin\u2013angiotensin system. Cancer Causes Control. 2022;33(2):313\u201320.","journal-title":"Cancer Causes Control"},{"key":"13273_CR13","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","volume":"7","author":"J Weberpals","year":"2017","unstructured":"Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk\u2013Sukel MPPV, et al. Pre- and post- diagnostic beta\u2013blocker use and lung cancer survival: a population\u2013based cohort study. Sci Rep. 2017;7:2911.","journal-title":"Sci Rep"},{"issue":"4","key":"13273_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/CEJ.0000000000000544","volume":"29","author":"M Coelho","year":"2020","unstructured":"Coelho M, Squizzato A, Cassina N, Marino F, Ribeiro LV, Cosentino M. Effect of beta\u2013blockers on survival of lung cancer patients: a systematic review and meta\u2013analysis. Eur J Cancer Prev. 2020;29(4):306\u201314.","journal-title":"Eur J Cancer Prev"},{"issue":"7","key":"13273_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1097\/HJH.0000000000002799","volume":"39","author":"G Kichenadasse","year":"2021","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Sorich MJ, Hopkins AM. Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes. J Hypertens. 2021;39(7):1274\u201381.","journal-title":"J Hypertens"},{"issue":"3","key":"13273_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bjc.2017.207","volume":"117","author":"OB Sanni","year":"2017","unstructured":"Sanni OB, Mc Menamin \u00daC, Cardwell CR, Sharp L, Murray LJ, Coleman HG. Commonly used medications and endometrial cancer survival: a population\u2013based cohort study. Br J Cancer. 2017;117(3):432\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"13273_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","volume":"121","author":"A Yap","year":"2018","unstructured":"Yap A, Lopez\u2013Olivo MA, Dubowitz J, Pratt G, Hiller J, Gottumukkala V, et al. Effect of beta\u2013blockers on cancer recurrence and survival: a meta\u2013analysis of epidemiological and perioperative studies. Br J Anaesth. 2018;121(1):45\u201357.","journal-title":"Br J Anaesth"},{"issue":"16","key":"13273_CR18","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/cncr.30079","volume":"122","author":"ZS Morris","year":"2016","unstructured":"Morris ZS, Saha S, Magnuson WJ, Morris BA, Borkenhagen JF, Ching A, et al. Increased tumour response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer. 2016;122(16):2487\u201395.","journal-title":"Cancer"},{"issue":"7","key":"13273_CR19","doi-asserted-by":"publisher","first-page":"e036164","DOI":"10.1136\/bmjopen-2019-036164","volume":"10","author":"R Ahl","year":"2020","unstructured":"Ahl R, Matthiessen P, Sj\u00f6lin G, Cao Y, Wallin G, Ljungqvist O, Mohseni S. Effects of beta\u2013blocker therapy on mortality after elective colon cancer surgery: a Swedish nationwide cohort study. BMJ Open. 2020;10(7):e036164.","journal-title":"BMJ Open"},{"key":"13273_CR20","doi-asserted-by":"publisher","first-page":"153473542311789","DOI":"10.1177\/15347354231178903","volume":"22","author":"HH Hsieh","year":"2023","unstructured":"Hsieh HH, Wu TY, Chen CH, Kuo YH, Hour MJ. Survival outcomes of calcium channel blocker therapy in patients with non-small cell lung cancer treated with epidermal growth factor receptor inhibitors: a retrospective study. Integr Cancer Ther. 2023;22:15347354231178903.","journal-title":"Integr Cancer Ther"},{"issue":"8","key":"13273_CR21","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/aje\/kwz106","volume":"188","author":"Y Cui","year":"2019","unstructured":"Cui Y, Wen W, Zheng T, Li H, Gao YT, Cai H, et al. Use of Antihypertensive Medications and Survival Rates for breast, colorectal, lung, or stomach Cancer. Am J Epidemiol. 2019;188(8):1512\u201328.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"13273_CR22","doi-asserted-by":"publisher","first-page":"e0245773","DOI":"10.1371\/journal.pone.0245773","volume":"16","author":"Z Lei","year":"2021","unstructured":"Lei Z, Yang W, Zuo Y. Beta-blocker and survival in patients with lung cancer: a meta-analysis. PLoS ONE. 2021;16(2):e0245773.","journal-title":"PLoS ONE"},{"key":"13273_CR23","doi-asserted-by":"publisher","first-page":"670657","DOI":"10.3389\/fphar.2021.670657","volume":"12","author":"Y Deng","year":"2022","unstructured":"Deng Y, Xie Y, Wang M, Xu P, Wei B, Li N, et al. Effects of antihypertensive drugs use on risk and prognosis of colorectal cancer: a meta\u2013analysis of 37 observational studies. Front Pharmacol. 2022;12:670657.","journal-title":"Front Pharmacol"},{"key":"13273_CR24","doi-asserted-by":"publisher","first-page":"117181","DOI":"10.1016\/j.lfs.2019.117181","volume":"242","author":"F Asgharzadeh","year":"2020","unstructured":"Asgharzadeh F, Hashemzehi M, Moradi\u2013Marjaneh R, Hassanian SM, Ferns GA, Khazaei M, et al. Angiotensin\u2013converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: a meta\u2013analysis. Life Sci. 2020;242:117181.","journal-title":"Life Sci"},{"issue":"1","key":"13273_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","volume":"26","author":"T Song","year":"2017","unstructured":"Song T, Choi CH, Kim MK, Kim ML, Yun BS, Seong SJ. The effect of angiotensin system inhibitors (angiotensin\u2013converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta\u2013analysis. Eur J Cancer Prev. 2017;26(1):78\u201385.","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"13273_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","volume":"23","author":"\u00daC Mc Menamin","year":"2012","unstructured":"Mc Menamin \u00daC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23(2):221\u201330.","journal-title":"Cancer Causes Control"},{"key":"13273_CR27","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M et al. (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today. Last accessed on 27 November 2023."},{"key":"13273_CR28","unstructured":"Bray F, Colombet M, Aitken JF, Bardot A, Eser S, Galceran J, et al. editors. (2023), Cancer Incidence in Five Continents, Vol. XII (IARC CancerBase No. 19). Lyon: International Agency for Research on Cancer. https:\/\/ci5.iarc.who.int, Last accessed on 22 October 2024."},{"key":"13273_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.04.004","volume":"47","author":"J Weberpals","year":"2016","unstructured":"Weberpals J, Jansen L, Carr PR, Hoffmeister M, Brenner H. Beta blockers and cancer prognosis - the role of immortal time bias: a systematic review and meta-analysis. Cancer Treat Rev. 2016;47:1\u201311.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"13273_CR30","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10654-021-00802-z","volume":"36","author":"S M\u00f6ller","year":"2021","unstructured":"M\u00f6ller S, Bliddal M, Rubin KH. Methodical considerations on adjusting for Charlson Comorbidity Index in epidemiological studies. Eur J Epidemiol. 2021;36(11):1123\u20138.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"13273_CR31","doi-asserted-by":"publisher","first-page":"djv045","DOI":"10.1093\/jnci\/djv045","volume":"107","author":"M Hoffmeister","year":"2015","unstructured":"Hoffmeister M, Jansen L, Rudolph A, Toth C, Kloor M, Roth W, et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst. 2015;107(6):djv045.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"13273_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1158\/1055-9965.EPI-15-0052","volume":"24","author":"CR Cardwell","year":"2015","unstructured":"Cardwell CR, Mc Menamin \u00da, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2015;24(5):833\u201341.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"13273_CR33","doi-asserted-by":"publisher","first-page":"e33411","DOI":"10.1371\/journal.pone.0033411","volume":"7","author":"H Noto","year":"2012","unstructured":"Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE. 2012;7(3):e33411.","journal-title":"PLoS ONE"},{"key":"13273_CR34","unstructured":"Lisauskien\u0117 I. Changes in Cardiovascular Medicines Utilization and Morbidity and Mortality from Cardiovascular Disease in Lithuania. Doctoral Dissertation. Vilnius: Vilnius University; 2017."},{"key":"13273_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-89836-9_368","volume-title":"Dictionary of Pharmaceutical Medicine","author":"G Nahler","year":"2009","unstructured":"Nahler G. Defined daily dose (DDD). Dictionary of Pharmaceutical Medicine. Vienna: Springer; 2009. https:\/\/doi.org\/10.1007\/978-3-211-89836-9_368."},{"key":"13273_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13027-017-0143-8","volume":"12","author":"R Everatt","year":"2017","unstructured":"Everatt R, Kuzmickiene I, Davidaviciene E, Cicenas S. Non-pulmonary cancer risk following tuberculosis: a nationwide retrospective cohort study in Lithuania. Infect Agent Cancer. 2017;12:33.","journal-title":"Infect Agent Cancer"},{"key":"13273_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1023\/B:EJEP.0000036568.02655.f8","volume":"19","author":"V Kristman","year":"2004","unstructured":"Kristman V, Manno M, C\u00f4t\u00e9 P. Loss to Follow-Up in Cohort studies: how much is too much? Eur J Epidemiol. 2004;19:751\u201360.","journal-title":"Eur J Epidemiol"},{"issue":"446","key":"13273_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"13273_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/1940-6207.CAPR-18-0288","volume":"12","author":"N Suzuki","year":"2019","unstructured":"Suzuki N, Niikura R, Ihara S, Hikiba Y, Kinoshita H, Higashishima N, et al. Alpha-blockers as Colorectal Cancer Chemopreventive: findings from a case-control study, human cell cultures, and in vivo preclinical testing. Cancer Prev Res (Phila). 2019;12(3):185\u201394.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"13273_CR40","first-page":"259","volume":"53","author":"I Lisauskien\u0117","year":"2017","unstructured":"Lisauskien\u0117 I, Garuolien\u0117 K, Gulbinovi\u010d J. Utilization of cardiovascular medicines and cardiovascular mortality in Lithuania, Sweden and Norway in 2003\u20132012. Med (Kaunas). 2017;53(4):259\u201367.","journal-title":"Med (Kaunas)"},{"issue":"1","key":"13273_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12964-021-00755-6","volume":"19","author":"M Archer","year":"2021","unstructured":"Archer M, Dogra N, Dovey Z, Ganta T, Jang HS, Khusid JA, et al. Role of \u03b1- and \u03b2-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease. Cell Commun Signal. 2021;19(1):78.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"13273_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/ijbs.68591","volume":"18","author":"T Huang","year":"2022","unstructured":"Huang T, Zhou J, Wang J. Calcium and calcium-related proteins in endometrial cancer: opportunities for pharmacological intervention. Int J Biol Sci. 2022;18(3):1065\u201378.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"13273_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11481-019-09891-w","volume":"15","author":"MB Nilsson","year":"2020","unstructured":"Nilsson MB, Le X, Heymach JV. \u03b2-Adrenergic signaling in Lung Cancer: a potential role for Beta-blockers. J Neuroimmune Pharmacol. 2020;15(1):27\u201336.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"9","key":"13273_CR44","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","volume":"41","author":"KY Fj\u00e6stad","year":"2022","unstructured":"Fj\u00e6stad KY, R\u00f8mer AMA, Goitea V, Johansen AZ, Thorseth ML, Carretta M, et al. Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumour microenvironment. Oncogene. 2022;41(9):1364\u201375.","journal-title":"Oncogene"},{"issue":"1","key":"13273_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/SLA.0000000000002970","volume":"271","author":"R Ahl","year":"2020","unstructured":"Ahl R, Matthiessen P, Fang X, Cao Y, Sjolin G, Lindgren R, et al. \u03b2\u2013blockade in rectal cancer surgery: a simple measure of improving outcomes. Ann Surg. 2020;271(1):140\u20136.","journal-title":"Ann Surg"},{"issue":"6","key":"13273_CR46","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/pcmr.12918","volume":"33","author":"NM Williams","year":"2020","unstructured":"Williams NM, Vincent LT, Rodriguez GA, Nouri K. Antihypertensives and melanoma: an updated review. Pigment Cell Melanoma Res. 2020;33(6):806\u201313.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"13273_CR47","doi-asserted-by":"publisher","first-page":"e172908","DOI":"10.1001\/jamaoncol.2017.2908","volume":"4","author":"V De Giorgi","year":"2018","unstructured":"De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma: results from a Cohort Study. JAMA Oncol. 2018;4(2):e172908.","journal-title":"JAMA Oncol"},{"issue":"7","key":"13273_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/CJI.0000000000000433","volume":"45","author":"OJ Kennedy","year":"2022","unstructured":"Kennedy OJ, Neary MT. Brief communication on the impact of \u03b2-blockers on outcomes in patients receiving Cancer Immunotherapy. J Immunother. 2022;45(7):303\u20136.","journal-title":"J Immunother"},{"issue":"9","key":"13273_CR49","doi-asserted-by":"publisher","first-page":"e3891","DOI":"10.1016\/j.urolonc.2014.11.022","volume":"33","author":"WF Ara\u00fajo","year":"2015","unstructured":"Ara\u00fajo WF, Naves MA, Ravanini JN, Schor N, Teixeira VP. Renin\u2013angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol. 2015;33(9):e3891\u20137.","journal-title":"Urol Oncol"},{"issue":"10","key":"13273_CR50","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00384-019-03379-y","volume":"34","author":"T Ozawa","year":"2019","unstructured":"Ozawa T, Hashiguchi Y, Yagi T, Fukushima Y, Shimada R, Hayama T, et al. Angiotensin I-converting enzyme inhibitors\/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers. Int J Colorectal Dis. 2019;34(10):1731\u20139.","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"13273_CR51","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3892\/or.2016.4887","volume":"36","author":"M Nowakowska","year":"2016","unstructured":"Nowakowska M, Matysiak-Burzy\u0144ska Z, Kowalska K, P\u0142uciennik E, Domi\u0144ska K, Piastowska-Ciesielska AW. Angiotensin II promotes endometrial cancer cell survival. Oncol Rep. 2016;36(2):1101\u201310.","journal-title":"Oncol Rep"},{"issue":"11","key":"13273_CR52","doi-asserted-by":"publisher","first-page":"9110","DOI":"10.1002\/jcb.27174","volume":"119","author":"ZE Matysiak-Burzy\u0144ska","year":"2018","unstructured":"Matysiak-Burzy\u0144ska ZE, Nowakowska M, Domi\u0144ska K, Kowalska K, P\u0142uciennik E, Piastowska-Ciesielska AW. Silencing of angiotensin receptor 1 interferes with angiotensin II oncogenic activity in endometrial cancer. J Cell Biochem. 2018;119(11):9110\u201321.","journal-title":"J Cell Biochem"},{"issue":"1","key":"13273_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ygyno.2012.04.020","volume":"126","author":"CH Choi","year":"2012","unstructured":"Choi CH, Park YA, Choi JJ, Song T, Song SY, Lee YY, et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-mir-155 and losartan on endometrial cancer cells. Gynecol Oncol. 2012;126(1):124\u201331.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"13273_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2022.2126250","volume":"23","author":"LT Maloney","year":"2022","unstructured":"Maloney LT, Latour E, Chen Y, Rice D, Grossblatt\u2013Wait A, Nabavizadeh N, et al. Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer. Cancer Biol Ther. 2022;23(1):1\u20138.","journal-title":"Cancer Biol Ther"},{"issue":"13","key":"13273_CR55","doi-asserted-by":"publisher","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","volume":"96","author":"H Sun","year":"2017","unstructured":"Sun H, Li T, Zhuang R, Cai W, Zheng Y. Do renin\u2013angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Evidence from a meta\u2013analysis including 55 studies. Med (Baltim). 2017;96(13):e6394.","journal-title":"Med (Baltim)"},{"issue":"6","key":"13273_CR56","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/CEJ.0000000000000018","volume":"23","author":"R Everatt","year":"2014","unstructured":"Everatt R, Kuzmickien\u0117 I, Virvi\u010di\u016bt\u0117 D, Tamo\u0161i\u016bnas A. Cigarette smoking, educational level and total and site-specific cancer: a cohort study in men in Lithuania. Eur J Cancer Prev. 2014;23(6):579\u201386.","journal-title":"Eur J Cancer Prev"},{"key":"13273_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1741-7015-12-28","volume":"12","author":"CR Cardwell","year":"2014","unstructured":"Cardwell CR, Mc Menamin \u00daC, Hicks BM, Hughes C, Cantwell MM, Murray LJ. Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med. 2014;12:28.","journal-title":"BMC Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13273-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13273-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13273-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:02:38Z","timestamp":1736373758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13273-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13273"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13273-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the study has been obtained from the Vilnius Regional Biomedical Research Ethics Committee, reference number: 2021\/3-1322-798. A waiver of written informed consent was granted by the Vilnius Regional Biomedical Research Ethics Committee, based at the Medical Faculty of Vilnius University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}